Seattle Cannabis Company Capitalizes on Surging Demand

From All Marijuana Stocks | Ad

The increase in the number of states that permit recreational and medical use of cannabis means that growers, processors and manufacturers of cannabis products often can’t keep up with growing demand. One Seattle weed manufacturer is poised to sell products across state lines, easing shortages. This could drive the company’s shares sky-high.

Get all the details on this potential blockbuster!

PTGX Insider Trading (Protagonist Therapeutics)

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 5.00%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $730,920.60

Protagonist Therapeutics Insider Trading History Chart

Protagonist Therapeutics Share Price & Price History

^$42.94

▼ -0.33 (-0.76%)

As of 06/24/2021 12:58 PM ET

Days: 30 | 90 | 365

Seattle Cannabis Company Capitalizes on Surging Demand

From All Marijuana Stocks | Ad

Get all the details on this potential blockbuster!

Protagonist Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/10/2021	Sarah B Noonberg	Director	Sell	4,700	$25.47	$119,709.00	4,700
1/19/2021	Dinesh V Ph D Patel	CEO	Sell	24,846	$24.60	$611,211.60	450,990
3/12/2020	Harold E Selick	Director	Buy	12,000	$6.70	$80,400.00	15,310
12/3/2019	Bryan Giraudo	Director	Buy	8,000	$5.70	$45,600.00	10,000
12/3/2019	Donald A Kalkofen	CFO	Buy	1,175	$5.10	$5,992.50	613
12/3/2019	Suneel Gupta	EVP	Buy	30,000	$5.13	$153,900.00	389,824
8/6/2019	David Y. Liu	Insider	Sell	3,395	$8.85	$30,045.75
8/6/2019	Dinesh V. Ph D. Patel	CEO	Sell	10,792	$8.85	$95,509.20
3/1/2019	Dinesh V Ph D Patel	CEO	Sell	2,183	$8.03	$17,529.49	386,014
3/1/2019	Richard S Shames	Insider	Sell	657	$8.03	$5,275.71	32,678
2/6/2019	David Y Liu	Insider	Sell	3,821	$7.74	$29,574.54	37,007
2/6/2019	Dinesh V Ph D Patel	CEO	Sell	10,909	$7.74	$84,435.66	367,396

Insider Selling at Protagonist Therapeutics?

Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Protagonist Therapeutics and related companies.

SEC Filings (Institutional Ownership Changes) for Protagonist Therapeutics (NASDAQ:PTGX)

Institutional Buying and Selling by Quarter

Protagonist Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/24/2021	Principal Financial Group Inc.	8,176	$0.21M	0.0%	N/A	0.019%
5/20/2021	Axiom Investment Management LLC	46,800	$1.22M	0.3%	N/A	0.106%
5/19/2021	Twin Lakes Capital Management LLC	142,884	$3.70M	2.3%	+0.3%	0.325%
5/18/2021	BVF Inc. IL	3,959,451	$102.55M	3.8%	-7.4%	9.010%
5/18/2021	Millennium Management LLC	10,892	$0.28M	0.0%	-52.2%	0.025%
5/18/2021	Canada Pension Plan Investment Board	55,000	$1.43M	0.0%	N/A	0.125%
5/18/2021	Opaleye Management Inc.	297,000	$7.69M	1.1%	+14.2%	0.676%
5/18/2021	Point72 Asset Management L.P.	942,300	$24.41M	0.1%	+71.3%	2.144%
5/18/2021	D. E. Shaw & Co. Inc.	200,980	$5.21M	0.0%	-40.3%	0.457%
5/18/2021	State of Wisconsin Investment Board	53,700	$1.39M	0.0%	-3.1%	0.122%
5/18/2021	Morgan Stanley	4,723	$0.12M	0.0%	-85.9%	0.011%
5/18/2021	Cubist Systematic Strategies LLC	14,700	$0.38M	0.0%	N/A	0.033%
5/18/2021	California State Teachers Retirement System	53,123	$1.38M	0.0%	+11.5%	0.121%
5/17/2021	Deerfield Management Company L.P. Series C	1,258,790	$32.60M	0.7%	-8.8%	2.864%
5/17/2021	AQR Capital Management LLC	30,387	$0.79M	0.0%	+29.7%	0.069%
5/17/2021	Royal Bank of Canada	3,324	$86K	0.0%	+179.3%	0.008%
5/17/2021	Price T Rowe Associates Inc. MD	913,590	$23.66M	0.0%	+8.1%	2.079%
5/17/2021	Ameriprise Financial Inc.	28,488	$0.74M	0.0%	-57.4%	0.065%
5/17/2021	Nuveen Asset Management LLC	144,700	$1.12M	0.0%	+28.5%	0.329%
5/17/2021	Sphera Funds Management LTD.	202,134	$5.24M	0.4%	N/A	0.460%
5/17/2021	Atom Investors LP	30,542	$0.79M	0.1%	-69.4%	0.070%
5/17/2021	Goldman Sachs Group Inc.	414,134	$10.73M	0.0%	-24.9%	0.942%
5/14/2021	Laurion Capital Management LP	147,405	$3.82M	0.0%	+13.3%	0.335%
5/14/2021	Kennedy Capital Management Inc.	75,518	$1.96M	0.0%	N/A	0.172%
5/14/2021	Birchview Capital LP	10,000	$0.26M	0.2%	N/A	0.023%
5/14/2021	RTW Investments LP	3,507,390	$90.84M	1.4%	-3.9%	7.981%
5/14/2021	Dimensional Fund Advisors LP	656,101	$16.98M	0.0%	+1.0%	1.493%
5/14/2021	TD Asset Management Inc.	61,471	$1.59M	0.0%	+19.9%	0.140%
5/14/2021	UBS Asset Management Americas Inc.	25,000	$0.65M	0.0%	+104.9%	0.057%
5/14/2021	Dynamic Technology Lab Private Ltd	8,202	$0.21M	0.0%	-19.3%	0.019%
5/14/2021	Credit Suisse AG	21,240	$0.55M	0.0%	-58.2%	0.048%
5/14/2021	Rothschild & Co. Asset Management US Inc.	434,249	$11.25M	0.1%	N/A	0.988%
5/14/2021	O Shaughnessy Asset Management LLC	2,206	$57K	0.0%	N/A	0.005%
5/13/2021	Trexquant Investment LP	10,522	$0.27M	0.0%	-41.8%	0.024%
5/13/2021	Axiom Investment Management LLC	46,800	$1.22M	0.2%	N/A	0.106%
5/13/2021	SG Americas Securities LLC	8,725	$0.23M	0.0%	N/A	0.020%
5/13/2021	Barclays PLC	37,866	$0.98M	0.0%	+257.0%	0.086%
5/13/2021	Bank of New York Mellon Corp	133,595	$3.46M	0.0%	+3.3%	0.304%
5/13/2021	Citigroup Inc.	95,720	$2.48M	0.0%	+886.1%	0.218%
5/13/2021	Bank of Montreal Can	90,073	$2.40M	0.0%	-32.6%	0.205%
5/12/2021	Northern Trust Corp	415,513	$10.76M	0.0%	+2.9%	0.946%
5/12/2021	Geode Capital Management LLC	645,679	$16.72M	0.0%	+27.0%	1.469%
5/12/2021	Prudential Financial Inc.	33,615	$0.87M	0.0%	-23.3%	0.076%
5/12/2021	JPMorgan Chase & Co.	584,897	$15.15M	0.0%	-16.8%	1.331%
5/12/2021	Panagora Asset Management Inc.	229,513	$5.94M	0.0%	-3.0%	0.522%
5/12/2021	E Fund Management Co. Ltd.	3,162	$82K	0.0%	N/A	0.007%
5/12/2021	Sei Investments Co.	86,880	$2.25M	0.0%	N/A	0.198%
5/12/2021	UBS Group AG	44,573	$1.15M	0.0%	-31.4%	0.101%
5/11/2021	Vontobel Holding Ltd.	10,000	$0.26M	0.0%	N/A	0.023%
5/10/2021	Russell Investments Group Ltd.	50,733	$1.31M	0.0%	-7.9%	0.115%
5/10/2021	Kestra Advisory Services LLC	13,629	$0.35M	0.0%	N/A	0.031%
5/10/2021	State Board of Administration of Florida Retirement System	8,630	$0.22M	0.0%	N/A	0.020%
5/10/2021	Principal Financial Group Inc.	8,176	$0.21M	0.0%	N/A	0.019%
5/10/2021	Rafferty Asset Management LLC	75,976	$1.97M	0.0%	+447.6%	0.173%
5/10/2021	Obermeyer Wood Investment Counsel Lllp	386,072	$10M	0.6%	N/A	0.879%
5/7/2021	BlackRock Inc.	3,001,629	$77.74M	0.0%	+15.8%	6.830%
5/7/2021	American International Group Inc.	20,527	$0.53M	0.0%	+12.2%	0.047%
5/7/2021	BNP Paribas Arbitrage SA	4,638	$0.12M	0.0%	-36.9%	0.011%
5/7/2021	Swiss National Bank	83,600	$2.17M	0.0%	+1.1%	0.190%
5/6/2021	Arizona State Retirement System	10,644	$0.28M	0.0%	N/A	0.024%
5/6/2021	Rhumbline Advisers	33,215	$0.86M	0.0%	-1.5%	0.076%
5/6/2021	Alliancebernstein L.P.	30,600	$0.79M	0.0%	+9.3%	0.070%
5/6/2021	Altium Capital Management LP	238,354	$6.17M	1.7%	+28.2%	0.542%
5/5/2021	Los Angeles Capital Management LLC	47,387	$1.23M	0.0%	-1.3%	0.108%
5/4/2021	Bingham Osborn & Scarborough LLC	15,640	$0.41M	0.0%	-39.0%	0.036%
5/3/2021	The Manufacturers Life Insurance Company	20,039	$0.52M	0.0%	+5.4%	0.046%
4/28/2021	Lindbrook Capital LLC	3,200	$83K	0.0%	+166.7%	0.007%
3/12/2021	DekaBank Deutsche Girozentrale	14,000	$0.30M	0.0%	N/A	0.037%
3/8/2021	Dimensional Fund Advisors LP	649,540	$13.10M	0.0%	-5.2%	1.698%
3/2/2021	Norges Bank	11,160	$0.23M	0.0%	N/A	0.029%
3/1/2021	UBS Asset Management Americas Inc.	12,200	$0.25M	0.0%	N/A	0.032%
2/26/2021	Twin Lakes Capital Management LLC	142,483	$2.87M	2.1%	N/A	0.372%
2/25/2021	Dimensional Fund Advisors LP	649,540	$13.10M	0.0%	-5.2%	1.698%
2/24/2021	Virtu Financial LLC	11,887	$0.24M	0.0%	N/A	0.031%
2/19/2021	JPMorgan Chase & Co.	703,007	$14.17M	0.0%	-10.4%	1.838%
2/17/2021	Jane Street Group LLC	14,473	$0.29M	0.0%	+9.1%	0.038%
2/16/2021	Silverarc Capital Management LLC	20,910	$0.42M	0.2%	N/A	0.055%
2/16/2021	Squarepoint Ops LLC	16,893	$0.34M	0.0%	N/A	0.044%
2/16/2021	Tri Locum Partners LP	259,283	$5.23M	1.9%	N/A	0.678%
2/16/2021	Baker BROS. Advisors LP	1,436,192	$28.95M	0.1%	-10.0%	3.754%
2/16/2021	Nuveen Asset Management LLC	112,571	$0.87M	0.0%	-0.6%	0.294%
2/16/2021	Price T Rowe Associates Inc. MD	845,395	$17.04M	0.0%	+44.3%	2.210%
2/16/2021	Engineers Gate Manager LP	13,030	$0.26M	0.0%	N/A	0.034%
2/16/2021	Gyon Technologies Capital Management LP	74,652	$1.51M	0.5%	N/A	0.195%
2/16/2021	ExodusPoint Capital Management LP	15,701	$0.32M	0.0%	N/A	0.041%
2/16/2021	Charles Schwab Investment Management Inc.	225,220	$4.54M	0.0%	+4.0%	0.589%
2/12/2021	Opaleye Management Inc.	260,000	$7.02M	0.9%	N/A	0.680%
2/12/2021	Laurion Capital Management LP	130,158	$2.62M	0.0%	N/A	0.340%
2/12/2021	Federated Hermes Inc.	42,992	$0.87M	0.0%	+40,844.8%	0.112%
2/12/2021	The Manufacturers Life Insurance Company	19,015	$0.38M	0.0%	+10.8%	0.050%
2/12/2021	Credit Suisse AG	50,823	$1.03M	0.0%	+85.0%	0.133%
2/12/2021	Virtus ETF Advisers LLC	14,102	$0.28M	0.1%	-26.0%	0.037%
2/11/2021	Lazard Asset Management LLC	2,607	$52K	0.0%	N/A	0.007%
2/11/2021	Trexquant Investment LP	18,074	$0.36M	0.0%	N/A	0.047%
2/11/2021	Northern Trust Corp	403,717	$8.14M	0.0%	+5.0%	1.055%
2/11/2021	Bingham Osborn & Scarborough LLC	25,640	$0.52M	0.0%	N/A	0.067%
2/11/2021	Barclays PLC	10,608	$0.21M	0.0%	-27.0%	0.028%
2/11/2021	Citigroup Inc.	9,707	$0.20M	0.0%	+302.6%	0.025%
2/11/2021	Dynamic Technology Lab Private Ltd	10,162	$0.21M	0.0%	N/A	0.027%
2/11/2021	Monashee Investment Management LLC	70,000	$1.41M	0.2%	N/A	0.183%

Data available starting January 2016

Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. It is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PTG-200, an oral, interleukin-23 receptor specific antagonist peptide, which is in phase II clinical trial for the treatment of moderate-to-severe Crohn's disease; and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase II clinical trial for treating inflammatory bowel disease (IBD). The company has a license and collaboration agreement with Janssen Biotech, Inc. for the development, manufacture, and commercialization of PTG-200 for the treatment of Crohn's disease and ulcerative colitis; and PN-235 and PN-232 oral interleukin-23 receptor antagonist candidates for IBD and non-IBD indications. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Today's Range

Now: $42.94

$42.56

$44.10

50 Day Range

MA: $33.20

$26.10

$43.44

52 Week Range

Now: $42.94

$14.16

$44.37

Volume

7,091 shs

Average Volume

386,169 shs

Market Capitalization

$1.89 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56

Who are the company insiders with the largest holdings of Protagonist Therapeutics?

Protagonist Therapeutics' top insider investors include:

Dinesh V Ph D Patel (CEO)
Suneel Gupta (EVP)
Harold E Selick (Director)
Bryan Giraudo (Director)
Sarah B Noonberg (Director)
Donald A Kalkofen (CFO)
David Y Liu (Insider)
Dinesh V Ph D Patel (CEO)

Who are the major institutional investors of Protagonist Therapeutics?

Protagonist Therapeutics' top institutional shareholders include:

BVF Inc. IL — 9.01%
RTW Investments LP — 7.98%
BlackRock Inc. — 6.83%
Deerfield Management Company L.P. Series C — 2.86%
Point72 Asset Management L.P. — 2.14%
Price T Rowe Associates Inc. MD — 2.08%

Which major investors are selling Protagonist Therapeutics stock?

Within the previous quarter, PTGX stock was sold by these institutional investors:

BVF Inc. IL
RTW Investments LP
Goldman Sachs Group Inc.
D. E. Shaw & Co. Inc.
Deerfield Management Company L.P. Series C
JPMorgan Chase & Co.
Atom Investors LP
Bank of Montreal Can

During the previous year, company insiders that have sold Protagonist Therapeutics company stock include:

Dinesh V Ph D Patel (CEO)
Suneel Gupta (EVP)

Which major investors are buying Protagonist Therapeutics stock?

Within the last quarter, PTGX stock was bought by institutional investors including:

Rothschild & Co. Asset Management US Inc.
BlackRock Inc.
Point72 Asset Management L.P.
Obermeyer Wood Investment Counsel Lllp
Sphera Funds Management LTD.
Geode Capital Management LLC
Sei Investments Co.
Citigroup Inc.

During the last year, these company insiders have bought Protagonist Therapeutics stock:

Dinesh V Ph D Patel (CEO)
Suneel Gupta (EVP)
Harold E Selick (Director)
Bryan Giraudo (Director)

Seattle Cannabis Company Capitalizes on Surging Demand

From All Marijuana Stocks | Ad

Get all the details on this potential blockbuster!